DFDA

Rituximab with CODOX-M/IVAC

Treatment for Burkitt Lymphoma

Typical Dosage: Complex multi-drug, dose-intensive regimen, intravenously in inpatient setting

Effectiveness
88%
Safety Score
25%
Clinical Trials
2
Participants
4K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Complex multi-drug, dose-intensive regimen, intravenously in inpatient setting
Time to Effect
Within weeks of starting cycles
Treatment Duration
4-5 months (4-6 cycles)
Evidence Quality
HIGH
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$140,000
Monitoring:$75,000
Side Effect Mgmt:$65,000
Total Annual:$280,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$60,000/QALY
QALYs Gained
5
Outcome-Based Costs
Cost per Responder
$329,411.76
Cost per Remission
$350,000
Rituximab with CODOX-M/IVAC Outcomes

for Burkitt Lymphoma

Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+85%
Remission Rate
+80%
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia, Anemia)
+95%
Febrile Neutropenia/Infection
+55%
Mucositis/Stomatitis
+65%
Nausea/Vomiting
+80%
Fatigue
+80%
Alopecia
+90%
Neurotoxicity (Vincristine-induced)
+35%
Renal Toxicity (Methotrexate, Ifosfamide-induced)
+15%

Sources:

nih.gov
ashpublications.org
thd.org.tr

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
2 completed trials for Rituximab with CODOX-M/IVAC in Burkitt Lymphoma

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

NCT00392990COMPLETEDPHASE2
View Study
25 participants
INTERVENTIONAL
Chicago, United States +7 more
Started: Feb 6, 2007

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

NCT00392834COMPLETEDPHASE2
View Study
34 participants
INTERVENTIONAL
La Jolla, United States +12 more
Started: Sep 1, 2006